X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3562) 3562
Publication (417) 417
Book Review (48) 48
Book Chapter (7) 7
Dissertation (5) 5
Conference Proceeding (4) 4
Book / eBook (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2750) 2750
index medicus (2160) 2160
protein-tyrosine kinases - antagonists & inhibitors (1264) 1264
female (1184) 1184
male (1184) 1184
oncology (1169) 1169
animals (1096) 1096
tyrosine (1019) 1019
protein-tyrosine kinase (907) 907
middle aged (815) 815
cancer (808) 808
aged (687) 687
protein kinase inhibitors - therapeutic use (675) 675
antineoplastic agents - therapeutic use (660) 660
adult (659) 659
antineoplastic agents - adverse effects (632) 632
kinases (602) 602
protein kinase inhibitors - adverse effects (591) 591
mice (499) 499
research (484) 484
treatment outcome (480) 480
mutation (466) 466
care and treatment (461) 461
pharmacology & pharmacy (452) 452
chemotherapy (446) 446
pyrimidines - adverse effects (426) 426
patients (418) 418
imatinib mesylate (416) 416
hematology (391) 391
pyrimidines - therapeutic use (389) 389
lung neoplasms - drug therapy (371) 371
tumors (360) 360
health aspects (346) 346
signal transduction (338) 338
carcinoma, non-small-cell lung - drug therapy (335) 335
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (332) 332
protein-tyrosine kinases - metabolism (332) 332
phosphorylation (323) 323
tyrosine kinase inhibitor (321) 321
benzamides (314) 314
medicine (307) 307
expression (300) 300
lung cancer (299) 299
leukemia (295) 295
protein kinase inhibitors - pharmacology (295) 295
metastasis (294) 294
therapy (290) 290
drug therapy (289) 289
proteins (288) 288
multidisciplinary sciences (284) 284
imatinib (282) 282
aged, 80 and over (280) 280
article (280) 280
receptor protein-tyrosine kinases - antagonists & inhibitors (277) 277
receptor protein-tyrosine kinases - genetics (268) 268
apoptosis (266) 266
research article (266) 266
analysis (265) 265
antineoplastic agents - pharmacology (264) 264
tyrosine kinase inhibitors (264) 264
survival (262) 262
protein kinase inhibitors - administration & dosage (259) 259
clinical trials (254) 254
genetic aspects (248) 248
cancer therapies (246) 246
signal transduction - drug effects (242) 242
antineoplastic agents - administration & dosage (241) 241
risk factors (240) 240
receptor protein-tyrosine kinases - metabolism (237) 237
cell biology (234) 234
biochemistry & molecular biology (232) 232
chronic myeloid leukemia (231) 231
science (230) 230
piperazines - adverse effects (228) 228
activation (227) 227
cell line, tumor (225) 225
neoplasms - drug therapy (225) 225
rats (225) 225
gene expression (224) 224
prognosis (223) 223
angiogenesis (222) 222
chronic myelogenous leukemia (216) 216
epidermal growth factor (215) 215
inhibitors (214) 214
piperazines - therapeutic use (208) 208
physiological aspects (206) 206
toxicity (206) 206
disease-free survival (205) 205
chronic myeloid-leukemia (196) 196
clinical trials as topic (195) 195
hemic and lymphatic diseases (189) 189
lung neoplasms - genetics (187) 187
abridged index medicus (184) 184
epidermal growth factor receptors (184) 184
pyrimidines - administration & dosage (184) 184
review (179) 179
dasatinib (178) 178
vascular endothelial growth factor (175) 175
lung cancer, non-small cell (174) 174
dose-response relationship, drug (173) 173
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3417) 3417
German (46) 46
Japanese (35) 35
Chinese (21) 21
French (21) 21
Hungarian (5) 5
Spanish (5) 5
Russian (4) 4
Dutch (3) 3
Norwegian (2) 2
Polish (2) 2
Swedish (2) 2
Croatian (1) 1
Czech (1) 1
Danish (1) 1
Italian (1) 1
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Blood, ISSN 0006-4971, 08/2015, Volume 126, Issue 6, pp. 739 - 745
Journal Article
ANNALS OF INTERNAL MEDICINE, ISSN 0003-4819, 08/2016, Volume 165, Issue 3, pp. 161 - 161
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2017, Volume 377, Issue 9, pp. 829 - 838
Alectinib, a potent ALK tyrosine kinase inhibitor, was more effective and somewhat less toxic than crizotinib when used as primary therapy in patients with ALK... 
RESISTANT | MEDICINE, GENERAL & INTERNAL | MODELS | ANTITUMOR-ACTIVITY | INHIBITOR ALECTINIB | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Central Nervous System Neoplasms - secondary | Young Adult | Pyridines - adverse effects | Anaplastic Lymphoma Kinase | Antineoplastic Agents - adverse effects | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Receptor Protein-Tyrosine Kinases - analysis | Pyrazoles - adverse effects | Pyridines - therapeutic use | Crizotinib | Carbazoles - adverse effects | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Animals | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Intention to Treat Analysis | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Central Nervous System Neoplasms - drug therapy | Drugs | Care and treatment | Analysis | Comparative analysis | Lung cancer, Non-small cell | Health aspects | Systemic diseases | Toxicity | Lung cancer | Central nervous system | Non-small cell lung carcinoma | Oncology | Nervous system | Metastasis | Radiation therapy | Patients | Lymphoma | Cancer therapies | Survival | Mutation | Protein-tyrosine kinase | Drug dosages | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2014, Volume 371, Issue 23, pp. 2167 - 2177
The ALK inhibitor crizotinib as first-line therapy was associated with a significantly better response rate, longer progression-free survival, and greater... 
CRITERIA | MEDICINE, GENERAL & INTERNAL | GEFITINIB | THERAPY | CISPLATIN | ADENOCARCINOMA | PHASE-III | KINASE | ANAPLASTIC LYMPHOMA | QLQ-C30 | PLUS | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Cisplatin - administration & dosage | Pyridines - adverse effects | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carboplatin - administration & dosage | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Glutamates - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Adenocarcinoma - mortality | Guanine - administration & dosage | Appetite | Edema | Inhibitor drugs | Intravenous administration | Biomedical research | Lung cancer | Diarrhea | Non-small cell lung carcinoma | Fatigue | Nausea | Metastasis | Patients | Cisplatin | Quality of life | Chemotherapy | Lungs | Platinum | Vomiting | Comparative studies | Carboplatin
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2016, Volume 374, Issue 4, pp. 323 - 332
Acalabrutinib is an irreversible inhibitor of Bruton's tyrosine kinase with greater specificity for the enzyme than the first-in-class agent, ibrutinib. It had... 
B-CELL RECEPTOR | MEDICINE, GENERAL & INTERNAL | ACTIVATION | IN-VIVO | X-LINKED AGAMMAGLOBULINEMIA | IBRUTINIB | BTK | PCI-32765 | TYROSINE KINASE INHIBITOR | LYMPHOMA | OPEN-LABEL | Recurrence | Benzamides - pharmacokinetics | Humans | Middle Aged | Pyrazines - administration & dosage | Male | Antineoplastic Agents - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Protein Kinase Inhibitors - adverse effects | Diarrhea - chemically induced | Dose-Response Relationship, Drug | Benzamides - administration & dosage | Antineoplastic Agents - adverse effects | Female | Antineoplastic Agents - pharmacokinetics | Benzamides - adverse effects | Headache - chemically induced | Chromosome Deletion | Protein Kinase Inhibitors - pharmacokinetics | Administration, Oral | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Agammaglobulinaemia Tyrosine Kinase | Pyrazines - pharmacokinetics | Pyrazines - adverse effects | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Treatment outcome | Usage | Care and treatment | Safety and security measures | Lymphocytic leukemia | Analysis | Clinical trials | Pharmacology | Dosage and administration | Pharmacokinetics | Antineoplastic agents | Tyrosine | Headache | Pharmacodynamics | Transformation | Chronic lymphatic leukemia | Inhibitor drugs | Leukemia | Diarrhea | Chromosome deletion | Lymphatic leukemia | Kinases | Lymphoma | Bruton's tyrosine kinase | Patients | Clonal deletion | Lymphomas | Safety | Drug therapy | Lymphocytosis | Protein-tyrosine kinase | Chromosome 17 | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2013, Volume 368, Issue 25, pp. 2385 - 2394
In a prospective, randomized, phase 3 trial of crizotinib as second-line therapy in patients who had disease progression while receiving a platinum-based... 
REARRANGEMENT | MEDICINE, GENERAL & INTERNAL | GEFITINIB | ONCOLOGY | EML4-ALK FUSION GENE | CLINICAL-TRIALS | PHASE-III | LYMPHOMA | OPEN-LABEL | DOCETAXEL | EGFR | Glutamates - therapeutic use | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Glutamates - adverse effects | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Young Adult | Taxoids - therapeutic use | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Guanine - adverse effects | Guanine - therapeutic use | Taxoids - adverse effects | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Quality of Life | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Tyrosine | Intravenous administration | Biomedical research | Lung cancer | Liver | Fatigue | Chromosome rearrangements | Cancer therapies | Patients | Lymphoma | Metastases | Ovarian cancer | Quality of life | Confidence intervals | Chemotherapy | Dyspnea | Alopecia | Platinum | Lymphomas | Respiration | Pharmaceutical industry | Protein-tyrosine kinase
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 22, pp. 2071 - 2082
Journal Article